


splicing therapeutics

Exonate

Exonate Limited was founded in 2013 and is based in Nottingham and Cambridge in the UK.

Exonate is a biopharmaceutical company focussed on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis), which is a key driver of disease progression in ophthalmic conditions and cancer

Exonate's founders have identified and generated a novel class of drugs, "SPHINXes," that modulate alternative mRNA splicing. They have developed a pipeline of molecules that promise therapeutics for anti-angiogenic therapies in ophthalmology, oncology, analgesia, diabetes, neurodegeneration and renal disease.



For further information please see: <http://exonate.com/>

Exonate Limited

This page has kindly been provided by: BANKIER SLOAN Chartered Surveyors
Banbury 01295 688384 reception@centre-p.co.uk www.centre-p.co.uk

July 2016

Exonate Limited